Amneal Pharmaceuticals, Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-08. 5 holders' latest filing reports 5% or more of class a common stock, par value $0.01. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Tushar Patel | 17.6% | 61,341,678 | SCHEDULE 13D/A, 2026-08-12 | 2026-08-10 |
| Chintu Patel | 9.4% | 32,576,528 | SCHEDULE 13D/A, 2026-08-12 | 2026-08-10 |
| Chirag Patel | 8.4% | 29,097,645 | SCHEDULE 13D/A, 2026-08-12 | 2026-08-10 |
| BlackRock, Inc. | 7.6% | 24,121,119 | SCHEDULE 13G, 2026-04-27 | 2026-03-31 |
| Patel Dipan | 5.4% | 16,904,263 | SCHEDULE 13D/A, 2026-03-26 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Purpose of Transaction (Item 4)
Chirag Patel
This Amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 7, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-12
Patel Dipan
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the New Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D. Between November 14, 2024 and December 31, 2025, trusts controlled by the Reporting Person sold 6,924,729 shares of Class A Common Stock in open market transactions at prices per share between $7.74 and $12.42.Item 4 of the SCHEDULE 13D/A filed 2026-03-26
Chintu Patel
This Amendment No. 5 to Schedule 13D (this "Amendment No. 5") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 5, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 5 shall have the meanings set forth in the Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-12
Tushar Patel
This Amendment No. 6 to Schedule 13D (this "Amendment No. 6") amends and supplements the Schedule 13D filed with the SEC on July 9, 2018 (the "Initial 13D" and, as amended and supplemented through the date of this Amendment No. 6, the "Schedule 13D"), by the Reporting Person relating to Class A Common Stock of the Issuer. Capitalized terms used but not defined in this Amendment No. 6 shall have the meanings set forth in the Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-08-12
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-08 | Patel Chirag K. | 7.1% | SCHEDULE 13D/A |
| 2025-10-06 | Patel Dipan | 7.6% | SCHEDULE 13D/A |
| 2025-10-07 | Patel Chintu | 8.2% | SCHEDULE 13D/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-03-26 | Patel Dipan | 5.4% | SCHEDULE 13D/A |
| 2026-04-27 | BlackRock, Inc. | 7.6% | SCHEDULE 13G |
| 2026-08-12 | Chintu Patel | 9.4% | SCHEDULE 13D/A |
| 2026-08-12 | Chirag Patel | 8.4% | SCHEDULE 13D/A |
| 2026-08-12 | Tushar Patel | 17.6% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Amneal Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.